Seaport Therapeutics, Inc. Common Stock (NASDAQ:SPTX) — Market Cap & Net Worth
Market Cap & Net Worth: Seaport Therapeutics, Inc. Common Stock (SPTX)
Seaport Therapeutics, Inc. Common Stock (NASDAQ:SPTX) has a market capitalization of $1.23 Billion ($1.23 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8012 globally and #2375 in its home market, demonstrating a -7.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seaport Therapeutics, Inc. Common Stock's stock price $22.96 by its total outstanding shares 53530550 (53.53 Million). Also see SPTX total asset value for a full breakdown of the balance sheet.
Seaport Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Seaport Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.23 Billion to $1.23 Billion (0.00% CAGR). Also see Seaport Therapeutics, Inc. Common Stock cash flow conversion for how efficiently the company converts equity into cash flow.
Seaport Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seaport Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Seaport Therapeutics, Inc. Common Stock (SPTX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SPTX by Market Capitalization
Companies near Seaport Therapeutics, Inc. Common Stock in the global market cap rankings as of September 16, 2026. Review Seaport Therapeutics, Inc. Common Stock (SPTX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Seaport Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Seaport Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Seaport Therapeutics, Inc. Common Stock's market cap moved from $1.23 Billion to $ 1.23 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Seaport Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.23 Billion USD |
| MoneyControl | $1.23 Billion USD |
| MarketWatch | $1.23 Billion USD |
| marketcap.company | $1.23 Billion USD |
| Reuters | $1.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more